BRIEF published on 07/24/2026 at 07:05, 3 months 16 days ago Update on Ipsen's Phase III BOLD Trial in Biliary Atresia Clinical Research Biliary Atresia Phase III BOLD Trial Odevixibat Liver Transplantation
PRESS RELEASE published on 07/24/2026 at 07:00, 3 months 16 days ago Ipsen provides update on Phase III BOLD trial in biliary atresia Ipsen's Phase III BOLD trial for biliary atresia did not meet primary endpoint. Bylvay safety profile confirmed. Insights gained will aid future research and patient care Ipsen Biliary Atresia Phase III BOLD Trial Bylvay Pediatric Liver Transplant
BRIEF published on 07/09/2026 at 07:05, 4 months ago Positive Phase III Results for Dysport® in the Treatment of Migraine Phase III Dysport Episodic Migraine Chronic Migraine Botulinum Toxin
BRIEF published on 07/09/2026 at 07:05, 4 months ago Dysport® Achieves Milestone in Migraine Phase III Trials Phase III Trials Dysport Episodic Migraine Chronic Migraine Botulinum Toxin
PRESS RELEASE published on 07/09/2026 at 07:00, 4 months ago Dysport® is the first botulinum toxin to achieve positive topline Phase III results in both episodic and chronic migraine. Dysport® achieves positive topline Phase III results in both episodic and chronic migraine, marking a significant advancement in migraine treatment Prevention Dysport® Botulinum Toxin Phase III Results Migraine
BRIEF published on 07/06/2026 at 12:02, 4 months 3 days ago BlackRock's stake in IPSEN SA fluctuates at the 5% threshold. Share Capital Voting Rights BlackRock Threshold Crossing Ipsen SA
BRIEF published on 06/29/2026 at 07:05, 4 months 10 days ago Ipsen to Acquire Kartos Therapeutics, Enhancing Hemato-Oncology Portfolio Hemato-oncology Ipsen Acquisition Ruxolitinib Myelofibrosis Navtemadlin
PRESS RELEASE published on 06/29/2026 at 07:00, 4 months 10 days ago Ipsen to acquire Kartos Therapeutics, expanding hemato-oncology late-stage pipeline Ipsen acquires Kartos Therapeutics, adding navtemadlin, a late-stage rare blood cancer asset in Phase III, to expand its Oncology portfolio. Top-line data from Phase III trial expected in 2027 Phase III Ipsen Hemato-oncology Navtemadlin Kartos Therapeutics
BRIEF published on 05/18/2026 at 07:05, 5 months 22 days ago Ipsen Initiates New Share Buy-back Program Share Buy-back Shareholder Value Investment Strategy Employee Share Plans Euronext: IPN
PRESS RELEASE published on 05/18/2026 at 07:00, 5 months 22 days ago Ipsen initiates a new share buy-back program Ipsen initiates new share buy-back program to purchase up to 350,000 shares, representing 0.42% of share capital. Program authorized by Annual General Meeting Share Buy-back Program Investment AGM Ipsen Employee Share-allocation
Published on 11/10/2026 at 02:45, 2 hours 26 minutes ago Presentation to Zurich Precious Metals Summit
Published on 11/09/2026 at 23:00, 6 hours 11 minutes ago LNG Energy Group Announces Issuance of Third Partial Revocation Order and Proposed Shares-for-Debt Settlement
Published on 11/09/2026 at 22:32, 6 hours 39 minutes ago Announces Extension for Closing of Private Placement of Convertible Promissory Notes
Published on 11/09/2026 at 22:15, 6 hours 56 minutes ago Goldcliff Announces Closing of the Second and Final Tranche of its "LIFE" Offering and Completion of Drilling at Kettle Valley
Published on 11/10/2026 at 04:55, 16 minutes ago The 19th Europe-China Business and Technology Cooperation Fair boosts business cooperation
Published on 11/10/2026 at 01:20, 3 hours 51 minutes ago US defence customer steps up orders and first graphene oxide orders secured
Published on 11/09/2026 at 22:54, 6 hours 17 minutes ago EQS-Adhoc: Northern Data Group reports Q3 2026 and raises its FY 2026 revenue outlook communicated on 17 June 2026
Published on 11/09/2026 at 22:10, 7 hours 1 minute ago Quantinuum to Participate in the Cantor Convergence 4th Annual Crypto, FinTech, AI & Energy Infrastructure Conference
Published on 11/09/2026 at 18:30, 10 hours 41 minutes ago Air Liquide has successfully issued a CHF 390 million multi-tranche bond
Published on 11/09/2026 at 17:35, 11 hours 36 minutes ago Disclosure of transactions in own shares from November 2 to November 6, 2026
Published on 11/09/2026 at 10:32, 18 hours 39 minutes ago Disclosure of shares outstanding and voting rights - 09.11.2026
Published on 11/09/2026 at 07:00, 22 hours 11 minutes ago bioMérieux receives U.S. FDA 510(k) clearance for the latest versions of the BIOFIRE® FILMARRAY® Gastrointestinal Panels to enhance detection of gastrointestinal pathogens including norovirus
